CC
NGNE icon

Casdin Capital’s Neurogene NGNE Stock Holding History

Casdin Capital’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$48.6M Buy
1,545,361
+125,000
+9% +$3.44M 2.43% 9
2026
Q1 		$28.6M Buy
1,420,361
+125,000
+10% +$2.42M 2.17% 12
2025
Q4 		$26.7M Hold
1,295,361
– – 1.66% 14
2025
Q3 		$22.4M Hold
1,295,361
– – 1.87% 12
2025
Q2 		$19.4M Hold
1,295,361
– – 1.76% 12
2025
Q1 		$15.2M Hold
1,295,361
– – 1.24% 15
2024
Q4 		$29.6M Buy
1,295,361
+770,745
+147% +$28.7M 1.97% 13
2024
Q3 		$22M Hold
524,616
– – 1.47% 17
2024
Q2 		$19.1M Hold
524,616
– – 1.46% 16
2024
Q1 		$26.7M Hold
524,616
– – 1.99% 16
2023
Q4 		$10.2M Buy
+524,616
New +$7.51M 1% 22

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Casdin Capital's NGNE Position: Q2 2026 in Review

Casdin Capital increased its Neurogene (NGNE) stake by 8.8% in Q2 2026, buying an estimated $3.44M and bringing the position to 1,545,361 shares worth $48.6M. The position accounts for 2.43% of the portfolio, ranked #9.

Casdin Capital first reported a position in NGNE in Q4 2023 and has held it in 11 quarters since. 111 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • Casdin Capital held 1,545,361 shares of Neurogene worth $48.6M as of Q2 2026.
  • Casdin Capital bought 125,000 Neurogene shares in Q2 2026, an estimated $3.44M.
  • Neurogene made up 2.43% of Casdin Capital's portfolio in Q2 2026, its #9 holding.
  • Casdin Capital first reported a position in Neurogene in Q4 2023 and has held it in 11 quarters since.
  • 111 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on Casdin Capital's 13F filing for Q2 2026, filed 14 Aug 2026.